<

Research and Publications

Publications

Stereotactic Radiosurgery in the Management of Non-Small Cell Lung Cancer Brain Metastases

Among this study’s authors are Anthony D’Ambrosio, MD, Co-Director of the Gamma Knife Center, and Willam Cobb, MD, PhD, Neurosurgeon at the Gamma Knife Center.

This paper represents a forward-looking (prospective) analysis combining the experience of 16 Stereotactic Radiosurgery (SRS) centers across America (including the Valley Gamma Knife Center). A total of 264 patients with non-small cell lung cancer (NSCLC) were cared for and the results were better than those of similar results from single centers. In particular, the overall survival of the patients managed through the NeuroPoint Alliance centers was superior to previous studies. In addition, local control of treated brain metastases was also excellent. Metastatic cancer from the lung to the brain is not uncommon but can be successfully managed using Gamma Knife Radiosurgery.

The Valley Gamma Knife Center participates in NeuroPoint Alliance’s Stereotactic Radiosurgery Registry, joining other institutions in voluntarily sharing patient data so outcomes can be collected in aggregate then reviewed, compared and studied on a wide range of patients across the country.

Treatment Outcomes for ARUBA-eligible Brain Arteriovenous Malformations

Among this study’s collaborators are Anthony D’Ambrosio, MD, Co-Director of the Gamma Knife Center, and Dorothea Altschul, MD, and Breehan Chancellor, MD, AVM Specialists at the Gamma Knife Center. An additional collaborator on this study is Jonathan Yun, MD, a member of The Valley Hospital Medical Staff.

Arteriovenous malformations (AVMs) of the brain can be managed in a variety of ways. If a patient or loved one is diagnosed with an AVM of the brain that has never bled (ruptured), it is sometimes unclear as to how one should best manage the patient and their AVM. There is much controversy in the medical community that exists regarding the “medical” management of an unruptured brain AVM versus the “surgical treatment” of an unruptured AVM.

This paper combines the experience of 18 participating comprehensive stroke centers (of which The Valley Hospital was one of), through the Neurovascular Quality Initiative-Quality Outcomes Database (NVQI-QOD), in treating a specific population of patients with unruptured AVMs. In this series, Gamma Knife Radiosurgery represented 37 of 173 patients and was considered a safe treatment option for a select subset of patients with unruptured AVMs of the brain.

The Valley Gamma Knife Center participates in the NVQI-QOD AVM registry, joining other institutions in voluntarily sharing patient data so outcomes can be collected in aggregate then reviewed, compared and studied on a wide range of patients across the country.

Clinical Trials

A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients With Resectable Brain Metastases

The Principal Investigator for this clinical trial is Rupa Juthani, M.D., neurosurgeon at The Valley Gamma Knife Center. This trial is open and enrolling.

This phase III trial compares the addition of stereotactic radiosurgery before or after surgery in treating patients with cancer that has spread to the brain (brain metastases). Stereotactic radiosurgery, such as Gamma Knife, is a type of radiation therapy that delivers a high dose of radiation only to the small areas of cancer in the brain and avoids the surrounding normal brain tissue.

Please click here for more details.